“Other expense decreased primarily due to a decrease in amortization of other intangible assets due to assets being amortized under an accelerated depreciation method, which results in higher expense recognition in earlier periods and progressively lower amort…”10-Q · Jul 15, 2026 ↗
Elevance Health, Inc.
ELV
Market read
Elevance Health, Inc.'s current read is isolated; its market group is not confirming.
No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- CarelonRx delegates certain core pharmacy services to CaremarkPCS (CVS) under an agreement with a contractual term through December 31, 2027.
Invalidation: The isolated read changes if ELV's group or a disclosed connection begins moving with it.
Research brief
The story so far
No new filing conclusion is available. 0 of 7 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
No thresholded supportive filing evidence is available yet.
No thresholded adverse filing evidence is available yet.
- CarelonRx delegates certain core pharmacy services to CaremarkPCS (CVS) under an agreement with a contractual term through December 31, 2027.
Company research
Understand the business, not just the ticker
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
- Which operating variable is changing?
- Is that change durable, cyclical or one-off?
- What evidence would disprove the current interpretation?
- Latest annual revenue changed +12.5% year over year.
- Credit and interest rates has repeated adverse evidence across 5 filings.
- P/E is 53% below the available filing-peer median; determine whether growth and quality justify the difference.
- EV/sales is 32% above the available filing-peer median; determine whether growth and quality justify the difference.
Price as of Sep 10, 2026
416.44Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
Persistent and emerging business drivers
“Net losses on financial instruments decreased due to lower impairment on other invested assets and lower realized losses on sales of financial instruments.”10-Q · Jul 15, 2026 ↗
“Operating loss decreased primarily due to the non-recurring accrual recorded during the year ended December 31, 2024 for the Provider Settlement Agreement associated with the BCBSA Litigation and lower business optimization charges in the year ended December…”10-K · Feb 6, 2026 ↗
“We intend to utilize this authorization over a multi-year period, subject to market and industry conditions.”10-K · Feb 6, 2026 ↗
Valuation discipline
Descriptive valuation snapshot
Price/sales 0.5× · EV/sales 0.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
How the market is pricing the story
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 10:55 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
No sourced recent-development timeline yet
Jodie has not returned a relevant primary source or news item for ELV. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Reported financial figures are not available yet
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Filing analysis
No comparable filing assessment is available yet
Jodie has not yet found a suitable current-versus-prior filing comparison for ELV. This does not mean the latest filing was neutral or immaterial.
Business ecosystem
The relationships behind ELV
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
CVSCVS Health CorporationpartnerFeb 6, 2026 ▾
“CarelonRx delegates certain core pharmacy services to CaremarkPCS Health, L.L.C., which is a subsidiary of CVS Health Corporation (“CVS”), pursuant to an agreement (the “CVS Agreement”) with the current contractual term extending through December 31, 2027.”
UNHUnitedHealth Group IncorporatedinvesteeFeb 6, 2026 ▾
“Boudreaux was Executive Vice President of UnitedHealth Group Incorporated (“UHGI”) (diversified healthcare company) from 2008 to 2015.”
Depended on by
CLOVClover Health Investments, Corp.competitorFeb 27, 2026 ▾
“Our competitors generally include large, national insurers, such as United Health, Aetna, Humana, Centene, and Elevance Health that provide MA plans, as well as regional-based companies or health plans that provide MA plans, including Blue Cross Blue Shield a…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 3 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
ELV is currently a Follower in the organic co-movement group Healthcare Plans. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
Theme membership history
No durable theme membership has been observed for this name yet.